1. Home
  2. CYCU vs SILO Comparison

CYCU vs SILO Comparison

Compare CYCU & SILO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cycurion Inc.

CYCU

Cycurion Inc.

HOLD

Current Price

$0.90

Market Cap

7.3M

Sector

N/A

ML Signal

HOLD

Logo Silo Pharma Inc.

SILO

Silo Pharma Inc.

HOLD

Current Price

$0.39

Market Cap

7.2M

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYCU
SILO
Founded
2017
2010
Country
United States
United States
Employees
74
N/A
Industry
Apparel
Sector
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
7.3M
7.2M
IPO Year
N/A
2011

Fundamental Metrics

Financial Performance
Metric
CYCU
SILO
Price
$0.90
$0.39
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$7.00
N/A
AVG Volume (30 Days)
1.3M
1.4M
Earning Date
06-05-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
57.98
EPS
N/A
N/A
Revenue
N/A
$72,102.00
Revenue This Year
$8.92
$1.86
Revenue Next Year
$10.00
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.16
$0.22
52 Week High
$7.13
$1.01

Technical Indicators

Market Signals
Indicator
CYCU
SILO
Relative Strength Index (RSI) 42.31 42.96
Support Level $0.77 $0.33
Resistance Level $1.08 $0.40
Average True Range (ATR) 0.10 0.04
MACD 0.01 -0.01
Stochastic Oscillator 43.23 11.12

Price Performance

Historical Comparison
CYCU
SILO

About CYCU Cycurion Inc.

Cycurion Inc. provides information technology security solutions through its subsidiaries. The Company continually strives to deliver top-notch services in risk management, cybersecurity, information assurance, systems engineering, and help desk solutions. The company generates the majority of its revenue from Advisory Consulting services, with small portion revenue generated from Managed Security Service Practice (MSSP) and Software as a Service (Saas).

About SILO Silo Pharma Inc.

SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's portfolio includes programs such as SPC-15 for PTSD, SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. The company's product pipelines include: SPC-14, SPC-15, SP-26, and SPU-16. The company operates as a single operating segment as a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical need.

Share on Social Networks: